{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:25:04Z","timestamp":1785414304744,"version":"3.56.0"},"reference-count":35,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Coronavirus disease 2019 (COVID-19) was recognised as a global pandemic in 2019, yet the exact number of infections is still unclear. In addition, there is limited research on post-mortem antibody testing.\n\nObjectives: This study sought to evaluate the use of the SureScreen COVID-19 immunoglobulin (Ig) G and IgM Rapid Test Cassette in deceased individuals by comparing it to the gold-standard antibody tests in South Africa, and to identify the most appropriate antibody testing method for post-mortem samples.\n\nMethod: Between May 2021 and February 2023, fifty cases, with suspected COVID-19 infection during their lifetime, were recruited from Tygerberg Mortuary and Salt River Mortuary, after obtaining informed consent from their next-of-kin. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed through antemortem positive COVID-19 polymerase chain reaction (PCR) (PCP) tests in 39 participants. Blood samples were collected during autopsies in serum separator tubes, which yielded better separation when centrifuged immediately after collection. The SureScreen test was performed alongside Roche Diagnostics Elecsys Anti-SARS-CoV-2 and Abbott Architect SARS-CoV-2 IgG assays.\n\nResults: Among the confirmed PCP cases, Elecsys demonstrated the highest sensitivity (97.1%) followed by SureScreen IgG (82.1%). In a logistic regression analysis, PCP confirmation was significantly associated with the SureScreen IgG results (p &lt; 0.05).\n\nConclusion: Overall, Roche\u2019s Elecsys had the highest yield of positive results on our cohort of post-mortem serum samples, followed by SureScreen, and finally, Abbott\u2019s Architect assay.\n\nContribution: These results suggest that the SureScreen test has potential as a screening tool in mortuary settings, with Roche\u2019s Elecsys assay recommended for diagnostic confirmation.\n\nKeywords: antibody screening; COVID-19; SARS-CoV-2; serology; post-mortem; lateral flow.<\/jats:p>","DOI":"10.4102\/sajid.v40i1.683","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:15:01Z","timestamp":1744272901000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A multicentre study comparing post-mortem SARS-CoV-2 antibody testing in Cape Town mortuaries"],"prefix":"10.4102","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-1489","authenticated-orcid":false,"given":"Tayna","family":"Carlisle","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4837-096X","authenticated-orcid":false,"given":"Yuvika","family":"Vandayar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-7314","authenticated-orcid":false,"given":"Laura","family":"Taylor","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9138-6719","authenticated-orcid":false,"given":"Itumeleng","family":"Molefe","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-7932","authenticated-orcid":false,"given":"Lorna J.","family":"Martin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1622-9558","authenticated-orcid":false,"given":"Candice","family":"Wilscott-Davids","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1273-5456","authenticated-orcid":false,"given":"Janette","family":"Verster","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6676-5431","authenticated-orcid":false,"given":"Christoffel","family":"Opperman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00znvbk37","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Laboratory Service"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4860-9419","authenticated-orcid":false,"given":"Laura J.","family":"Heathfield","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"ref0","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard [homepage on the Internet]. 2024 [cited 2024 Jan 18]. Available from: https:\/\/covid19.who.int\/"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"French MA, Moodley Y. The role of SARS-CoV-2 antibodies in COVID-19: Healing in most, harm at times. Respirology. 2020;25(7):680\u2013682. https:\/\/doi.org\/10.1111\/resp.13852","DOI":"10.1111\/resp.13852"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):940\u2013948. https:\/\/doi.org\/10.1080\/22221751.2020.1762515","DOI":"10.1080\/22221751.2020.1762515"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Toll\u00e5nes MC, Bakken Kran AM, Abildsnes E, Jenum PA, Breivik AC, Sandberg S. Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2. Clin Chem Lab Med. 2020;58(9):1595\u20131600. https:\/\/doi.org\/10.1515\/cclm-2020-0628","DOI":"10.1515\/cclm-2020-0628"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nakano Y, Kurano M, Morita Y, et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021;11(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-021-82428-5","DOI":"10.1038\/s41598-021-82428-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Rodr\u00edguez A, Casas I, Culebras E, Morilla E, Cohen MC, Alberola J. COVID-19 and post-mortem microbiological studies. Span J Legal Med. 2020;46(3):127\u2013138. https:\/\/doi.org\/10.1016\/j.remle.2020.05.007","DOI":"10.1016\/j.remle.2020.05.007"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Xiao K, Yang H, Liu B, et al. Antibodies can last for more than 1 year after SARS-CoV-2 infection: A follow-up study from survivors of COVID-19. Front Med (Lausanne). 2021;8:1\u201310. https:\/\/doi.org\/10.3389\/fmed.2021.684864","DOI":"10.3389\/fmed.2021.684864"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chansaenroj J, Yorsaeng R, Puenpa J, et al. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients. PLoS One. 2022;17(4):1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0267102","DOI":"10.1371\/journal.pone.0267102"},{"key":"ref8","unstructured":"Abbott Laboratories. SARS-CoV-2 IgG for use with architect [homepage on the Internet]. 2021 [cited 2022 May 30]. Available from: https:\/\/www.fda.gov\/media\/137383\/download"},{"key":"ref9","unstructured":"Roche Diagnostics. Elecsys\u00ae anti-SARS-CoV-2 S [homepage on the Internet]. 2022 [cited 2022 Jul 28]. Available from: https:\/\/diagnostics.roche.com\/global\/en\/products\/params\/elecsys-anti-sars-cov-2-s.html#productSpecs"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem. 2016;60(1):111\u2013120. https:\/\/doi.org\/10.1042\/EBC20150012","DOI":"10.1042\/EBC20150012"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Muench P, Jochum S, Wenderoth V, et al. Development and validation of the Elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58(10):e01694-20. https:\/\/doi.org\/10.1128\/JCM.01694-20","DOI":"10.1128\/JCM.01694-20"},{"key":"ref12","unstructured":"Roche Diagnostics. Elecsys\u00ae anti-SARS-CoV-2 immunoassay for the qualitative detection of antibodies against SARS-CoV-2 [homepage on the Internet]. 2020 [cited 2022 May 30]. Available from: https:\/\/diagnostics.roche.com\/us\/en\/products\/lab\/elecsys-anti-sars-cov-2-cps-000273.html"},{"key":"ref13","unstructured":"SureScreen Diagnostics. COVID-19 coronavirus rapid test cassette. 2020 [cited 2020 Aug 12]. Available from: https:\/\/www.surescreen.com\/products\/covid-19-coronavirus-rapid-test-cassette"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Jugwanth S, Gededzha MP, Mampeule N, et al. Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022;17(2):e0262442. https:\/\/doi.org\/10.1371\/journal.pone.0262442","DOI":"10.1371\/journal.pone.0262442"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Wilkemeyer I, Pruss A, Kalus U, Schroeter J. Comparative infectious serology testing of pre- and postmortem blood samples from cornea donors. Cell Tissue Bank. 2012;13:447\u2013452. https:\/\/doi.org\/10.1007\/s10561-012-9326-0","DOI":"10.1007\/s10561-012-9326-0"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Victer TNdF, Dos Santos CSR, B\u00e1o SN, Sampaio TL. Deceased tissue donor serology and molecular testing for HIV, hepatitis B and hepatitis C viruses: A lack of cadaveric validated tests. Cell Tissue Bank. 2016;17:543\u2013553. https:\/\/doi.org\/10.1007\/s10561-016-9564-7","DOI":"10.1007\/s10561-016-9564-7"},{"key":"ref17","unstructured":"South African Health Products Regulatory Authority. SAHPRA approves SARS-CoV-2 serology test kits [homepage on the Internet]. 2020 [cited 2023 Jun 01]. Available from: https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2020\/08\/Media-release-SAHPRA-approves-SARS-COV-2-serology-test-kits-.pdf"},{"key":"ref18","unstructured":"SAHPRA. SAHPRA registered health products [homepage on the Internet]. 2022 [cited 2022 Jul 24]. Available from: https:\/\/www.sahpra.org.za\/registered-health-products\/"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Grove JS, Mayne ES, Burgers WA, et al. Validation of Roche immunoassay for severe acute respiratory coronavirus 2 in South Africa. S Afr J Infect Dis. 2021;36(1):1\u20136. https:\/\/doi.org\/10.4102\/sajid.v36i1.286","DOI":"10.4102\/sajid.v36i1.286"},{"key":"ref20","unstructured":"Carlisle T. Comparison of SARS-CoV-2 rapid tests and formal serological testing on deceased persons in Cape Town metro [minor research dissertation]. Cape Town: University of Cape Town; 2022 [cited n.d.]. Available from: https:\/\/open.uct.ac.za\/server\/api\/core\/bitstreams\/c2518868-20eb-4917-a756-48fbcc22d9fc\/content"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Reid KM, Martin LJ, Heathfield LJ. Bodies without names: A retrospective review of unidentified decedents at Salt River Mortuary, Cape Town, South Africa, 2010\u20132017. S Afr Med J. 2020;110(3):223\u2013228. https:\/\/doi.org\/10.7196\/SAMJ.2020.v110i3.14192","DOI":"10.7196\/SAMJ.2020.v110i3.14192"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Edler C, Wulff B, Schr\u00f6der AS, et al. A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death. J Med Microbiol. 2011;60(7):920\u2013926. https:\/\/doi.org\/10.1099\/jmm.0.027763-0","DOI":"10.1099\/jmm.0.027763-0"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kalus U, Wilkemeyer I, Caspari G, et al. Validation of the serological testing for anti-HIV-1\/2, anti-HCV, HBsAg, and anti-HBc from post-mortem blood on the siemens-BEP-III automatic system. Transfus Med Hemotherapy. 2011;38(6):365\u2013372. https:\/\/doi.org\/10.1159\/000334481","DOI":"10.1159\/000334481"},{"key":"ref24","unstructured":"Roche Diagnostics. Elecsys anti-SARS-CoV-2 S [homepage on the Internet]. 2021 [cited 2021 Aug 11]. Available from: https:\/\/www.fda.gov\/media\/144037\/download"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Liu R, Liu X, Yuan L, et al. Analysis of adjunctive serological detection to nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Int Immunopharmacol. 2020;86:106746. https:\/\/doi.org\/10.1016\/j.intimp.2020.106746","DOI":"10.1016\/j.intimp.2020.106746"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity. Immunity. 2020;53(5):925\u2013933.e4. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.004","DOI":"10.1016\/j.immuni.2020.10.004"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;92(9):1518\u20131524. https:\/\/doi.org\/10.1002\/jmv.25727","DOI":"10.1002\/jmv.25727"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Johnston S, McKay P, Kebadze T, et al. Evaluation of the Abbott architect, Roche Elecsys and virtus S1 SARS-CoV-2 antibody tests in community-managed COVID-19 cases. medRxiv. 2020;10(7):20220509. https:\/\/doi.org\/10.1101\/2020.10.27.20220509","DOI":"10.1101\/2020.10.27.20220509"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"De Giorgi V, West KA, Henning AN, et al. Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection. J Infect Dis. 2021;224(8):1294\u20131304. https:\/\/doi.org\/10.1093\/infdis\/jiab295","DOI":"10.1093\/infdis\/jiab295"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Tan SS, Saw S, Chew KL, et al. Comparative clinical evaluation of the Roche Elecsys and Abbott severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology assays for coronavirus disease 2019 (COVID-19). Arch Pathol Lab Med. 2021;145(1):32\u201338. https:\/\/doi.org\/10.5858\/arpa.2020-0499-SA","DOI":"10.5858\/arpa.2020-0499-SA"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Suhandynata RT, Bevins NJ, Tran JT, et al. SARS-CoV-2 serology status detected by commercialized platforms distinguishes previous infection and vaccination adaptive immune responses. J Appl Lab Med. 2021;6(5):1109\u20131122. https:\/\/doi.org\/10.1093\/jalm\/jfab080","DOI":"10.1093\/jalm\/jfab080"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Stringhini S, Zaballa M-E, Pullen N, et al. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance. 2021;26(43):2100830. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.43.2100830","DOI":"10.2807\/1560-7917.ES.2021.26.43.2100830"},{"key":"ref33","unstructured":"MU Health Care. What you need to know about the Johnson & Johnson COVID-19 vaccine [homepage on the Internet]. 2021 [cited 2022 Jul 10]. Available from: https:\/\/www.muhealth.org\/our-stories\/what-you-need-know-about-johnson-johnson-covid-19-vaccine#:~:text=The scientists behind the Johnson,t replicate or cause illness"},{"key":"ref34","unstructured":"The Immunisation Advisory Centre. How cominarty is made and what it contains [homepage on the Internet]. 2022 [cited 2022 July 10]. Available from: https:\/\/covid.immune.org.nz\/how-comirnaty-made-and-what-it-contains"}],"container-title":["Southern African Journal of Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/683\/1760","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/683\/1761","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/683\/1762","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/683\/1764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/683\/1763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/view\/683\/1763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T08:34:34Z","timestamp":1756974874000},"score":1,"resource":{"primary":{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/view\/683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/sajid.v40i1.683","relation":{},"ISSN":["2312-0053","2313-1810"],"issn-type":[{"value":"2312-0053","type":"print"},{"value":"2313-1810","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"article-number":"a683"}}